Orforglipron Reduces Breathing Interruptions in Sleep Apnea
Oral drug trials in adults with sleep apnea and excess weight showed fewer nightly breathing pauses alongside weight and blood pressure reductions.
Updated on Nov. 9, 2026 in Weight Loss
Live Poll
Would you consider a daily pill for sleep apnea if your doctor recommended it?
Orforglipron reduced breathing interruptions during sleep in adults with moderate-to-severe sleep apnea and excess weight across two 52-week trials. The results were presented at the AHA Scientific Sessions and published in JAMA.
Why it matters
Obesity is a significant risk factor for sleep apnea, and the trials suggest an oral medication could address both conditions at once. The findings add to a growing body of research on weight-loss drugs as a treatment approach for the disorder.
In the randomized trials of 712 adults, breathing interruptions fell by about 18 per hour with orforglipron versus about 5 with placebo after 52 weeks. Researchers have not yet determined whether mechanisms beyond weight loss drove the improvement, and long-term cardiovascular effects require further study.
The players
Eli Lilly and Company
A major American pharmaceutical company that developed orforglipron and funded the trials.
American Heart Association
A leading U.S. nonprofit focused on cardiovascular health, which hosted the Scientific Sessions where the results were presented.
The details
Participants were randomly assigned to orforglipron or placebo, and neither researchers nor participants knew which they received. Breathing interruptions were measured through overnight sleep studies at baseline, week 24 and week 52, while body weight fell about 10-11% in the orforglipron groups compared with 1-2% in the placebo groups. The most common side effects were nausea, diarrhea and constipation, and Eli Lilly and Company funded the studies.
Timeline
October 2024: Trials began enrolling at 66 medical centers worldwide.
July 2026: Trials concluded across North America, South America, Europe and Asia.
November 9, 2026: Results were presented at AHA Scientific Sessions in Chicago and published in JAMA.
Health Landscape
The trial extends the GLP-1 receptor agonist class, which has been used mainly for diabetes and weight management, into obstructive sleep apnea, a condition traditionally treated with CPAP devices or surgery. If approved for this use, orforglipron would offer an oral alternative in a field where treatment has largely required mechanical or surgical intervention.
If approved for obstructive sleep apnea, orforglipron would be an oral option for people with overweight or obesity who struggle with the condition. The most common side effects reported were nausea, diarrhea and constipation, which patients would need to weigh against the benefits.
The takeaway
Sleep apnea and excess weight often occur together, so treatments that address body weight may also ease nightly breathing problems. Anyone with symptoms such as loud snoring or daytime fatigue should discuss evaluation and treatment options with a clinician.
Further reading
For more on how medications are being studied for weight and related conditions, see Weight Loss.
Live Poll
Would you consider a daily pill for sleep apnea if your doctor recommended it?
